21 July 2022  
EMA/CHMP/653247/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Tecartus 
brexucabtagene autoleucel 
On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Tecartus. 
The marketing authorisation holder for this medicinal product is Kite Pharma EU B.V. 
The CHMP adopted a new indication for the treatment of acute lymphoblastic leukaemia (ALL). For 
information, the full indication for Tecartus will therefore be as follows:2 
Mantle cell lymphoma 
Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell 
lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine 
kinase (BTK) inhibitor.  
Acute lymphoblastic leukaemia 
Tecartus is indicated for the treatment of adult patients 26 years of age and above 
with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
